Spots Global Cancer Trial Database for Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL

Official Title: Prospective Multicenters Clinical Cohort Study on Efficacy and Safety of Stratified Treatment for Chinese Children With Burkitt Lymphoma/Diffuse Large B-cell Lymphoma

Study ID: NCT03958916

Conditions

Rituximab

Lymphoma, Non-Hodgkin

Pediatric Cancer

Interventions

Study Description

Brief Summary: The trial SCCCG-BL/DLBCL-2017 is a collaborative prospective, multicenters, non-randomized, observational, cohort clinical study with participating centers of the South China Children's Cancer Group-Non-Hodgkin lymphoma group(SCCCG-NHL). The aim of the study is to evaluate efficacy and safety of stratified treatment based on risk factors of childhood and adolescents Burkitt lymphoma(BL)/diffuse large B-cell lymphoma(DLBCL) patients in china.

Detailed Description: Research purposes: 1. To investigate the efficacy and safety of SCCCG-BL/DLBCL-2017 in children with BL and DLBCL. 2. To investigate the effect of rituximab combined with chemotherapy on the survival rate of children with high-risk BL/DLBCL. 3. To investigate the effect of rituximab on immune function in children with high-risk BL/DLBCL. 4. To explore the correlation between MRD detection and the efficacy and survival of children with BL/DLBCL. 5. To explore the role of PET/CT in evaluating residual lesions in children after BL/DLBCL treatment.